EZH2 and synovial sarcoma: Patients with stage II and stage III synovial sarcoma had significantly higher EZH2 scores (2.188 ± 0.3788, p = 0.0437 and 2.200 ± 0.3524, p = 0.0388, respectively) than stage I patients (1.077 ± 0.3483).